journal
MENU ▼
Read by QxMD icon Read
search

Expert Opinion on Biological Therapy

journal
https://www.readbyqxmd.com/read/29788767/limitations-of-current-monoclonal-antibodies-for-plaque-type-psoriasis-and-an-outlook-for-the-future
#1
Annunziata Raimondo, Anna Balato, Matteo Megna, Nicola Balato
No abstract text is available yet for this article.
May 23, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29782188/an-evaluation-of-nivolumab-for-the-treatment-of-metastatic-renal-cell-carcinoma
#2
Kevin Zarrabi, Shenhong Wu
The treatment paradigm for metastatic renal cell carcinoma (mRCC) has undergone a revolution with the rapid market approval of multiple agents over a three-year period. The immunogenicity of RCC provided the biological rationale to assess the clinical efficacy of nivolumab, an immune checkpoint inhibitor. Nivolumab is approved for second-line treatment after failure of angiogenesis targeted therapy and in combination therapy with ipilimumab for previously untreated intermediate or poor-risk advanced renal cell carcinoma...
May 21, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29781343/issues-and-promises-of-bevacizumab-in-prostate-cancer-treatment
#3
Vittore Cereda, Vincenzo Formica, Mario Roselli
There is general agreement that increased angiogenesis is an important factor in determining prostate cancer development and prognosis. Vascular Endothelial Growth Factor (VEGF) is thought to play a primary role in the molecular events that lead to prostate cancer progression, from androgen-dependency to castration-resistance until dissemination to the skeleton. Bevacizumab is a recombinant anti-VEGF monoclonal antibody that has exhibited clinical activity in different cancer types. Areas covered: In this review we summarize the data of clinical trials, investigating the effects of bevacizumab in prostate cancer patients...
May 21, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29781327/the-progress-of-aav-mediated-gene-therapy-in-neuromuscular-disorders
#4
Sara Aguti, Alberto Malerba, Haiyan Zhou
The well-defined genetic causes and monogenetic nature of many neuromuscular disorders, including Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA), present gene therapy as a prominent therapeutic approach. The novel variants of adeno-associated virus (AAV) can achieve satisfactory transduction efficiency of exogenous genes through the central nervous system and body-wide in skeletal muscle. Areas covered: In this review, we summarize the strategies of AAV gene therapy that are currently under preclinical and clinical evaluation for the treatment of degenerative neuromuscular disorders, with a focus on diseases such as DMD and SMA...
May 20, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29781319/assessing-the-role-of-ranibizumab-in-improving-the-outcome-of-glaucoma-filtering-surgery-and-neovascular-glaucoma
#5
Andreas Katsanos, Kostantina Gorgoli, Dimitrios G Mikropoulos, Esther Arranz-Marquez, Georgios P Athanasopoulos, Miguel A Teus, Anastasios G P Konstas
Ranibizumab was the first anti-vascular endothelial growth factor (VEGF) agent approved for the treatment of neovascular age-related macular degeneration. The use of ranibizumab and other anti-VEGF medications in recent years has revolutionized the treatment of several sight-threatening retinal disorders. Emerging evidence has demonstrated that anti-VEGF treatment can offer advantages in the management of other ocular conditions where VEGFs play a key role: ocular scarring following glaucoma filtering surgery and neovascular glaucoma (NVG)...
May 19, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29718723/sirna-drug-development-against-hepatitis-b-virus-infection
#6
Robert Flisiak, Jerzy Jaroszewicz, Mariusz Łucejko
Hepatitis B virus (HBV) infection is the worldwide leading cause of liver cirrhosis and hepatocellular carcinoma. Currently available medication can suppress viral replication in the majority of patients, but clearance of the viral antigens can be achieved in only about 10%. Areas covered: RNA interference is a very attractive therapeutic option since a well-designed compound could possibly inhibit all HBV mRNA and thus synthesis of all its antigens, which could combine antiviral and immunomodulatory modes of action...
May 8, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29681203/the-immunotherapy-of-guillain-barr%C3%A3-syndrome
#7
Paula Restrepo-Jiménez, Yhojan Rodríguez, Paulina González, Christopher Chang, M Eric Gershwin, Juan-Manuel Anaya
Guillain-Barré syndrome is the most common cause of acute flaccid paralysis worldwide. Microorganisms such as Campylobacter jejuni, Cytomegalovirus, Epstein-Barr virus, Mycoplasma pneumoniae, Haemophilus influenzae and Zika virus have been linked to the disease. The most common clinical variants are acute inflammatory demyelinating polyneuropathy and acute motor axonal neuropathy. Plasma exchange and intravenous immunoglobulins are the standard therapy for the disease. Areas covered: research to elucidate the pathophysiology of Guillain-Barré syndrome has led to the development of drugs directed towards new potential therapeutic targets...
May 8, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29727246/strategies-for-enhancing-adoptive-t-cell-immunotherapy-against-solid-tumors-using-engineered-cytokine-signaling-and-other-modalities
#8
Thomas Shum, Robert L Kruse, Cliona M Rooney
Cancer therapy has been transformed by the demonstration that tumor-specific T-cells can eliminate tumor cells in a clinical setting with minimal long-term toxicity. However, significant success in the treatment of leukemia and lymphoma with T-cells using native receptors or redirected with chimeric antigen receptors (CARs) has not been recapitulated in the treatment of solid tumors. This lack of success is likely related to the paucity of costimulatory and cytokine signaling available in solid tumors, in addition to a range of inhibitory mechanisms...
May 4, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29727205/thymosin-%C3%AE-4-a-key-modifier-of-renal-disease
#9
Elisavet Vasilopoulou, Paul R Riley, David A Long
There is an urgent need for new treatments for chronic kidney disease (CKD). Thymosin-β4 is a peptide that reduces inflammation and fibrosis and has the potential to restore endothelial and epithelial cell injury, biological processes involved in the pathophysiology of CKD. Therefore, thymosin-β4 could be a novel therapeutic direction for CKD. Areas covered: Here, we review the current evidence on the actions of thymosin-β4 in the kidney in health and disease. Using transgenic mice, two recent studies have demonstrated that endogenous thymosin-β4 is dispensable for healthy kidneys...
May 4, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29688797/progress-with-infliximab-biosimilars-for-inflammatory-bowel-disease
#10
Zsuzsanna Kurti, Lorant Gonczi, Peter L Lakatos
Biological therapies have revolutionized the treatment of inflammatory bowel diseases (IBD) in the last two decades. Though biological drugs are effective, their use is associated with high costs and access to biological agents varies among countries. As the patent for the reference products expired, the advent of biosimilar monoclonal antibodies has been expected. Biosimilars represent less expensive alternatives compared to the reference product. Areas covered: In this review, authors will review the literature on the clinical efficacy, safety and immunogenicity of current and future biosimilar infliximabs...
April 29, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29690797/atezolizumab-for-the-treatment-of-breast-cancer
#11
Debora Basile, Giacomo Pelizzari, Maria Grazia Vitale, Camilla Lisanti, Marika Cinausero, Donatella Iacono, Fabio Puglisi
Breast cancer (BC) is the most common cancer diagnosed among women. The development of new personalized therapeutic strategies has reshaped the landscape in this field. However, BC is still the first cause of death among women. Interestingly, several preclinical studies and some clinical evidences are focused their attention on the role of immune system and immunotherapy on cancer control, also in BC. Areas covered: Usually, BC has been considered a not immunogenic tumor for its low mutational load. However, recent studies have evidenced that some subtypes, triple negative and HER-2 positive BC, are "hot" tumors, thus more immunogenic...
April 24, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29623726/the-effect-of-biological-dmards-on-the-risk-of-congestive-heart-failure-in-rheumatoid-arthritis-a-systematic-review
#12
Milad Baniaamam, Walter J Paulus, Annelies B Blanken, Michael T Nurmohamed
A common cardiovascular manifestation in rheumatoid arthritis (RA) is congestive heart failure (CHF) in which inflammation is considered to play a pivotal role. Although anti-inflammatory therapy such as biological disease-modifying anti-rheumatic drugs (bDMARDs) have the potential of improving the cardiac function and reducing the risk of CHF, the published studies showed contrasting results. This review aims to systematically summarize and analyze literature regarding the effect of bDMARDs on the cardiac function and on the risk of CHF in RA...
April 23, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29681195/biologics-for-treating-axial-spondyloarthritis
#13
Alexis Jones, Coziana Ciurtin, Mediola Ismajli, Maria Leandro, Raj Sengupta, Pedro M Machado
Spondyloarthritis (SpA) encompasses a heterogeneous group of diseases sharing genetic, immunological, clinical and imaging features. Axial spondyloarthritis (axSpA) refers to a subgroup characterised predominately by inflammation of the axial skeleton with subsequent symptoms of chronic (often inflammatory) back pain and sacroiliitis. There is a strong association with the major histocompatibility complex (MHC) class I allele human leukocyte antigen (HLA) B27. In the last decade, there has been significant progress in earlier detection of the disease and the molecular mechanisms involved in its pathogenesis...
April 21, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29633865/uptake-of-rheumatology-biosimilars-in-the-absence-of-forced-switching
#14
Daniela Di Giuseppe, Thomas Frisell, Sofia Ernestam, Helena Forsblad-D'Elia, Elisabet Lindqvist, Ulf Lindström, Christopher Sjöwall, Johan Askling
BACKGROUND: To describe the uptake and system-level effects of the introduction of biosimilars in a setting without forced switching. RESEARCH DESIGN AND METHODS: We used data from the Swedish Rheumatology Quality register from start of marketing of infliximab (Remsima® and Inflectra®) and etanercept (Benepali®) biosimilars until 31 December 2016. We compared users of each originator-product and its biosimilar(s) by line of treatment: bDMARD-naïve patients, non-medical switchers (vs...
April 10, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29624084/recent-developments-in-interferon-based-therapies-for-multiple-sclerosis
#15
Laura Dumitrescu, Cris S Constantinescu, Radu Tanasescu
Multiple sclerosis (MS) is a chronic and disabling immune-mediated disease of the central nervous system. Beta-interferons are the first approved and still the most widely used first-line disease-modifying treatment in MS. Areas covered: Here we focus on recent developments in pharmacology and delivery systems of beta-interferons, and discuss their place within current state of the art therapeutic approaches. We briefly review the clinical trials for classical and PEGylated formulations, emphasizing effectiveness, safety concerns, and tolerability...
April 6, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29557205/is-cell-therapy-the-answer-for-hematological-malignancies
#16
Pasquale Niscola, Paolo de Fabritiis
No abstract text is available yet for this article.
March 20, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29502471/sources-of-variability-in-quantifying-circulating-thymosin-beta-4-literature-review-and-recommendations
#17
Warren K Y Tan, Kristy Purnamawati, Leroy S Pakkiri, Sock Hwee Tan, Xiaoxun Yang, Mark Y Chan, Chester L Drum
Thymosin beta-4 (TB4) is an endogenous peptide with protective and regenerative effects in models of cellular and organ injury. TB4 is increasingly measured as a potential plasma or serum biomarker in human cardiovascular, liver, infectious, and autoimmune disease. Areas covered: The focus of this review is the quantification of TB4 in clinical cohort studies and whether reported TB4 concentrations differ with respect to method of sample preparation. We survey current literature for studies measuring TB4 in human serum or plasma and compare reported concentrations in healthy controls...
March 12, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29508629/thymosin-beta-4-regulation-of-actin-in-sepsis
#18
Justin B Belsky, Emanuel P Rivers, Michael R Filbin, Patty J Lee, Daniel C Morris
Sepsis is the dysregulated host response to an infection resulting in life-threatening organ damage. Thymosin Beta 4 is an actin binding protein that inhibits the polymerization of G-actin into F-actin and improves mortality when administered intravenously to septic rats. Thymosin Beta 4 decreases inflammatory mediators, lowers reactive oxygen species, up-regulates anti-oxidative enzymes, anti-inflammatory genes, and anti-apoptotic enzymes making it an interesting protein to study in sepsis. Areas covered: The authors summarize the current knowledge of actin and Thymosin Beta 4 as it relates to sepsis via a comprehensive literature search...
March 6, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29474790/thymosin-induced-immunoregulation-clinical-potentials-for-allergy-and-asthma-endotypes
#19
Gailen Marshall
No abstract text is available yet for this article.
March 6, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29471701/repairing-the-corneal-epithelium-using-limbal-stem-cells-or-alternative-cell-based-therapies
#20
Yuzuru Sasamoto, Bruce R Ksander, Markus H Frank, Natasha Y Frank
The corneal epithelium is maintained by limbal stem cells (LSCs) that reside in the basal epithelial layer of the tissue surrounding the cornea termed the limbus. Loss of LSCs results in limbal stem cell deficiency (LSCD) that can cause severe visual impairment. Patients with partial LSCD may respond to conservative therapies designed to rehabilitate the remaining LSCs. However, if these conservative approaches fail or, if complete loss of LSCs occurs, transplantation of LSCs or their alternatives is the only option...
March 6, 2018: Expert Opinion on Biological Therapy
journal
journal
39827
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"